Minerva Neurosciences (NERV) Accumulated Expenses (2013 - 2026)

Minerva Neurosciences has reported Accumulated Expenses for 14 years, with the latest figure at $40750.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 33.41% year-over-year to $40750.0; the trailing twelve-month figure through Mar 2026 stood at $40750.0 (down 33.41% YoY), and the FY2024 full-year result was $363181.0, down 38.52% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $40750.0, down from $1.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $1.1 million in Q3 2022, with the low at $14832.0 in Q4 2022.
• Historically, Accumulated Expenses has averaged $401186.6 across 5 years, with a median of $223491.5 in 2023.
• The largest YoY upside for Accumulated Expenses was 3883.07% in 2023 against a maximum downside of 92.98% in 2023.
• Minerva Neurosciences' Accumulated Expenses stood at $14832.0 in 2022, then soared by 3883.07% to $590769.0 in 2023, then plunged by 38.52% to $363181.0 in 2024, then surged by 187.53% to $1.0 million in 2025, then tumbled by 96.1% to $40750.0 in 2026.
• The last three Accumulated Expenses figures came in at $40750.0 (Q1 2026), $1.0 million (Q3 2025), and $756394.0 (Q2 2025), per Business Quant data.